Reolysin is an oncolytic virus commercialized by Oncolytics Biotech, with a leading Phase II program in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer). According to Globaldata, it is involved in 48 clinical trials, of which 38 were completed, 6 are ongoing, 2 are planned, and 2 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Reolysin’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Reolysin is expected to reach an annual total of $70 mn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Reolysin Overview
Oncolytics Biotech Overview
Oncolytics Biotech is a development stage biopharmaceutical company which focuses on the discovery and development of oncolytic viruses for the treatment of cancer. The company’s lead product candidate, pelareorep, is an unmodified reovirus that is an intraosseous (I-O) viral agent indicated for systemic administration for the treatment of hematological malignancies and solid tumors. It is advancing pelareorep as a combination with other products in various clinical phases for the treatment of metastatic breast cancer (BC), early-stage BC, pancreatic cancer, and relapsed or refractory multiple myeloma. Oncolytics Biotech is headquartered in Calgary, Alberta, Canada.
The operating loss of the company was CAD26.9 million in FY2022, compared to an operating loss of CAD26.2 million in FY2021. The net loss of the company was CAD24.8 million in FY2022, compared to a net loss of CAD26.3 million in FY2021.
For a complete picture of Reolysin’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.